Amit Etkin, Alto Neuroscience CEO

Al­to touts new PhI­Ia de­pres­sion da­ta with plans to keep charg­ing for­ward

SAN FRAN­CIS­CO — Pri­vate biotech Al­to Neu­ro­science re­vealed new da­ta Tues­day morn­ing for a psy­chi­atric drug it’s so ex­cit­ed about that a fol­low-up study is al­ready en­rolling.

Al­to tout­ed open-la­bel Phase IIa re­sults for lead pro­gram AL­TO-100, in which the biotech ex­am­ined im­prove­ments in a de­pres­sion symp­tom rat­ing scale known as MADRS. Re­searchers com­pared the change in MADRS scores for pa­tients with and with­out pre-de­fined bio­mark­ers, and the dif­fer­ence proved sta­tis­ti­cal­ly sig­nif­i­cant in both monother­a­py and ad­junc­tive co­horts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.